Xencor, Inc. XNCR 深 沪
已收盘 02-06 16:00:00 美东时间
11.61
+0.790
+7.30%
华盛通- 最 高11.65
- 今 开11.14
- 成交量 63.01万股
- 最 低 11.01
- 昨 收 10.82
- 总市值 8.29亿
- 52周最高 18.69
- 市盈率 静 --
- 换手率 0.88%
- 52周最低 6.92
- 委 比 26.32%
- 总股本 7141.05万
- 历史最高 58.345
- 量 比 1.22
- 振 幅 5.91%
- 历史最低 5.75
- 每 手 1
- 风险率 3.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Xencor Faces Structural Headwinds As Long-Term Momentum Fades
Why Xencor Stock's current weakness may persist and why rallies ahead are unlikely to sustain.
2025-12-18 19:25
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
Barclays Maintains Overweight on Xencor, Raises Price Target to $26
Barclays analyst Etzer Darout maintains Xencor (NASDAQ:XNCR) with a Overweight and raises the price target from $23 to $26.
2025-12-18 02:01
Incyte announces EU approval of Xencor-partnered lymphoma therapy
Incyte (INCY) announced on Wednesday that the European Commission approved a drug regimen containing its Xencor (XNCR)-partnered antibody drug Minjuvi as a late-line option for certain adults with fol...
2025-12-18 00:52
Xencor’s New Study on XmAb657: A Potential Game-Changer for Muscle Diseases
Xencor Inc. ($XNCR) announced an update on their ongoing clinical study. Study ...
2025-12-17 00:30
Xencor Secures New US Patent, Extending Ultomiris Royalties By Three Years And Unlocking Up To $120M In Additional Revenue
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the issuance of U.S. Patent 12,492,253, which
2025-12-09 20:11
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
Truist Securities Initiates Coverage On Xencor with Buy Rating, Announces Price Target of $29
Truist Securities analyst Gregory Renza initiates coverage on Xencor (NASDAQ:XNCR) with a Buy rating and announces Price Target of $29.
2025-11-25 02:04
Candel pausing development of CAN-2409 in prostate cancer type
Candel Therapeutics (CADL) said it is pausing the development of CAN-2409 specifically for an indication in borderline resectable pancreatic adenocarcinoma, where it is in phase 2 testing. The company...
2025-11-15 00:47
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
2025-11-07 10:14
